No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
PHC Holdings Corporation, through its network of subsidiaries, specializes in the innovation, production, and sale of medical instruments, advanced healthcare technology solutions, and life science merchandise. The company's product line includes blood glucose monitoring systems and a variety of other diagnostic and analytical tools, alongside sophisticated data integration platforms. It also delivers end-to-end anatomical pathology solutions, featuring specialized equipment, microscope slides, and diverse staining reagents. In the life sciences sector, PHC provides essential equipment and support services for sample preservation and cell culture. Furthermore, the company develops and deploys healthcare IT products, focusing on medical information systems designed for clinics and pharmacies dealing with health insurance. Its operations also extend to clinical testing, the manufacturing of diagnostic reagents, and providing support for pharmaceutical development. Established in 2014 and based in Tokyo, Japan, the company was formerly recognized as Panasonic Healthcare Holdings Co., Ltd. before officially changing its name to PHC Holdings Corporation in April 2018.
www.phchd.com/jpNo one on the platform currently holds 6523.T.
No tracked institution reports a position in 6523.T as of their last filing.
No one on the platform has traded 6523.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 0.4% | — | — | — | ||
| Rev. Growth % | 0.8% | 3.6% | ||||
| Profit Margin % | 0.1% | -0.8% | ||||
| Free Cash Flow Margin % | 9.2% | 7.9% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $373.8B | +2.5% | $160.04 | $113.96–$203.01 | — | 6 |
| 2028 | $380.6B | +1.8% | $167.49 | $136.96–$201.48 | — | 6 |
| 2029 | $389.9B | +2.4% | $180.20 | $145.13–$207.12 | — | 5 |
| 2030 | $410.3B | +5.2% | $205.30 | $196.73–$211.92 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $21.97 | $50.06 | +127.9% |
| 2026-05-13 | $15.83 | $-1.60 | -110.1% |
| 2026-02-12 | $13.50 | $9.92 | -26.5% |
| 2025-11-12 | $25.35 | $14.13 | -44.3% |
| 2025-08-07 | $3.95 | $-18.55 | -569.6% |
| 2025-05-13 | $35.86 | $22.55 | -37.1% |
| 2025-02-12 | $29.57 | $28.06 | -5.1% |
| 2024-11-13 | $16.66 |
| $57.67 |
| +246.2% |
| +0.51% |
| $147.9B |
| — |
| 4549.TEiken Chemical Co., Ltd. | $2260.00 | +0.22% | $74.5B | — |
| 4553.TTowa Pharmaceutical Co., Ltd. | $3625.00 | +2.11% | $178.5B | — |
Source: Financial Modeling Prep · peers by sector/industry